Scientific topics
Keywords
ITMO
Claire MAGNON PharmD, PhD
Course and current status
EDUCATION
2016 French habilitation for supervising research (HDR, Habilitation à Diriger des Recherches)
2005 PhD -Oncology. Graduated with First Class Honors with congratulations from the jury
University of Paris XI, Gustave Roussy Institut-Cancer Center, Villejuif, France
2002 PharmD (Former Resident in Medical Biology specialized in Cell and Gene Therapy).
Graduated with First Class Honors with congratulations from the jury
School of Medicine and Pharmacy-Paris V, René Descartes University, France
2000 Advanced Diploma in Biotechnology (DEA: Diplôme d’Etudes Approfondies)
University of Paris VII-Saint Louis hospital-Graduated with honors
1998 National Diploma in Statistics. Graduated with honors
C.E.S.A.M, Centre d’Enseignement de la Statistique Appliquée à la Médecine et à la Biologie Médicale, Paris, France
1997 National Competitive Residency Examination in Medical Biology
School of Medicine and Pharmacy-Paris V, René Descartes University, France
1997 Master in Medical Biology. Graduated with honors
MSBM, Maîtrise des Sciences Biologiques et Médicales
1996 National Diploma in Molecular Biology. Graduated with honors
Paris V René Descartes University. Cochin Hospital
1995 National Diploma in Biochemistry. Graduated with honors
Paris V René Descartes University. Necker Hospital
1992 National Competitive Examination in Pharmacy
School of Medicine and Pharmacy-Paris V, René Descartes University, France
PROFESSIONNAL EMPLOYMENT and HOSPITAL APPOINTMENTS
2015-Present ATIP-AVENIR group leader (INSERM/CNRS)
IBFJ/iRCM/UMR967, France
2015-present Scientific advisor (CEA)
IBFJ/iRCM/UMR967, France
2013-2014 Researcher CEA. IBFJ/iRCM/UMR967, France
2010-2012 Tenure-Track Assistant Professor
Albert Einstein College of Medicine, Institute for Stem Cell and Regenerative Medicine, NY, USA
2007-2009 Post-Doctoral Fellow
Mount Sinai chool of Medicine, Department of Medicine and Gene and Cell Medicine, Tisch Cancer Institute. NY, USA
2005-2007 Attending Clinical Biologist (Praticien Hospitalier contractuel)
- Necker Hospital, Department of Hematology and Immunology, France
- Gustave Roussy Institute - Cancer Center, Clinical Laboratory of Cell Therapy, France
2003-2005 Young researcher (Poste d’accueil Inserm for MD/PharmD)
Gustave Roussy Institute - Cancer Center. Laboratory of Vectorology and Gene Transfer, France
1997-2002 Resident in Medical Biology
Assistance Publique-Hôpitaux de Paris (AP-HP), France
Scientific summary
Convergence of multiple stromal cell types is required to develop a tumorigenic niche that nurtures the initial development of cancer and its dissemination. While the immune and vascular systems have been described as having robust influences on cancer, a growing body of evidences points to the role of the nervous system in promoting cancer development. Our laboratory ( Science 12 July 2013: Vol. 341 no. 6142 ) uncovered that sympathetic and parasympathetic nerve fibers from the autonomic nervous system (ANS) infiltrate prostate tumors and contribute to the early stages of cancer development as well as tumor invasion and metastasis. We have now characterized the process of neo-neurogenesis in primary tumors and metastasis. Doublecortine (DCX+) neural progenitors leave the subventricular zone, a neurogenic niche in the brain, and circulate through the blood to home into primary tumor and metastasis where they can differentiate into adrenergic neurons to sustain early stages of tumor development (Nature 15 May 2019: advance online publication). The nervous system interacts with the immune and vascular systems to maintain homeostasis in the brain and peripheral organs. Therefore, we are conducting additional studies to further characterize a neurogenic, immune and vascular interactome in the brain and in tumors involved in controlling cancer development. Understanding biological systems or pathways that might be regulated by the central or peripheral nervous system in tumors will be pivotal to developing novel cancer therapies.
